A New Approach for Medicamentous Treatment of Patients with Lower Urinary Tract Symptoms Caused by Benign Prostate Hyperplasia and Chronic Prostatitis. Is It Possible to Prevent the Prostate Cancer?


Oleh Nikitin
Yaroslav Klymenko
Mykola Yasynetskyi
Hennadii Reznikov
Volodymyr Sych


Today the lower urinary tract symptoms (LUTS) in men are the actual problem. LUTS is an extremely polyetiological problem, but benign prostate hyperplasia (BPH) is the most often reason for its development.

The problem of chronic prostatitis (CP) in patient of the older age with BPH is of great importance. These patients have the most pronounced symptoms of the lower urinary tract dysfunction. The therapy of patients with BPH and CP must lead to reducing of LUTS and improvement of quality of life, as well as to complications prevention associated with prostate enlargement and intravesical obstruction, such as acute urinary retention, recurrent urinary tract infection.

The modern researches have presented that the combinations of herbal preparation with tamsulosin were more effective than monotherapy with α-adrenoblockers. That is why phytotherapy is considered an alternative option in the treatment of CP as first-line therapy and for the BPH initial stages in the complex treatment with other drugs. In contrast to “traditional” measures with one component, today multicomponent herbal preparations are popular.

A natural complex preparation which contains saw palmetto extract (S. Repens), 3.3’ diindolylmethane, pumpkin seed extract, resveratrol, lycopene for hormonal balance normalization for men with BPH was analyzed.

The advantage of the natural complex hormonal balance normalization for men with BPH is that it can be prescribed for the first LUTS signs that can prevent the symptoms progression and development of complications.

Urologist received the preparation for effective LUTS treatment in patients with BPH and CP, as well for removal of postoperative dysuria.


How to Cite
Nikitin, O., Klymenko, Y., Yasynetskyi, M., Reznikov, H., & Sych, V. (2022). A New Approach for Medicamentous Treatment of Patients with Lower Urinary Tract Symptoms Caused by Benign Prostate Hyperplasia and Chronic Prostatitis. Is It Possible to Prevent the Prostate Cancer?. Health of Man, (4), 24–30. https://doi.org/10.30841/2307-5090.4.2022.274434
Topical issues
Author Biographies

Oleh Nikitin, Bogomolets National Medical University

Oleh D. Nikitin,

MD, PhD, DSc, Professor, Head of the Department of Urology

Yaroslav Klymenko, Bogomolets National Medical University

Yaroslav M. Klymenko,

MD, PhD, Аssociate Professor, Department of Urology

Mykola Yasynetskyi, Bogomolets National Medical University

 Mykola O. Yasynetskyi,

MD, Assistant of Professor

Hennadii Reznikov, Bogomolets National Medical University

Hennadii D. Reznikov,

MD, Assistant of Professor

Volodymyr Sych, Bogomolets National Medical University

Volodymyr I. Sych,

MD, PhD student, Department of Urology


Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12–9. doi: 10.1080/13685538.2018.1434772.

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46(5):547–54. doi: 10.1016/j.eururo.2004.07.016.

Kamalov AA, Takhirzade AM. Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction. Urol. 2018;(3):70–7.

Ficarra V. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)? BJU Int. 2013;112(4):421–2. doi: 10.1111/bju.12177.

Vynohradov YV. Evaluation of the efficacy and tolerability of combination therapy for lower urinary tract symptoms in patients with chronic prostatitis and benign prostatic hyperplasia. Experimental Clin Urol. 2021;14(1):37–43. doi: 10.29188/2222-8543-2021-14-1-37-42.

McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007;29(3):387–98. doi: 10.1016/s0149-2918(07)80077-4.

Bhatt NR, Davis NF, Witjes WP, Bjartell A, Caris C, Patel A, et al. Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry. World J Urol. 2021;39(7):2661–7. doi: 10.1007/s00345-020-03480-w.

Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745–55. doi: 10.1093/ageing/afv077.

Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol. 2019;28(6):1599–606. doi: 10.1007/s10068-019-00605-9.

Wu TY, Khor TO, Su ZY, Saw CL, Shu L, Cheung KL, et al. Epigenetic modifications of Nrf2 by 3,3‘-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J. 2013;15(3):864–74. doi: 10.1208/s12248-013-9493-3.

Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, Koukoulis G, et al. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol. 2019;37(3):539–44. doi: 10.1007/s00345-018-2409-1.

Silvestri I, Cattarino S, Agliano A, Nicolazzo C, Scarpa S, Salciccia S, et al. Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. J Inflamm (Lond). 2013;10:11. doi: 10.1186/1476-9255-10-11.

Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30(3):227–81. doi: 10.1038/aps.2009.1.

Scaglione F. How to Choose the Right Serenoa repens Extract. Eur Urol Suppl. 2015;14(9):e1464–9. doi: 10.1016/S1569-9056(15)30501-7.

Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana LB, Fernández-Gómez JM, Angulo JC, et al. Efficacy and safety of a hexanic extract of Serenoa repens (PermixonR ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049–65. doi: 10.1111/bju.14362.

Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Permixon in benign prostatic hyperplasia. Prostate. 2000;45(3):259-66. doi:10.1002/1097-0045(20001101)45:3<259::aidpros9>3.0.co;2-g.

Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, et al. Anti-androgenic activity of absorption-enhanced 3, 3‘-diindolylmethane in prostatectomy patients. Am J Transl Res. 2016;8(1):166–76.

Geller J, Sionit L, Partido C, Li L, Tan X, Youngkin T, et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate. 1998;34(2):75-9. doi: 10.1002/(sici)1097-0045(19980201)34:2<75::aid-pros1>3.0.co;2-i.

Zhang WW, Feng Z, Narod SA. Multiple therapeutic and preventive effects of 3,3‘-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. J Biomed Res. 2014;28(5):339–48. doi: 10.7555/JBR.28.20140008.

Bosutti A, Zanconati F, Grassi G, Dapas B, Passamonti S, Scaggiante B. Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem. 2016;16(11):1385–402. doi: 10.2174/1871520616666160425105257.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res. 2012;4(1):14–23.

Le HT, Schaldach CM, Firestone GL, Bjeldanes LF. Plant-derived 3,3‘-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem. 2003;278(23):21136–45. doi: 10.1074/jbc.M300588200.

Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, et al. The phytochemical 3,3‘-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells. J Nutr Biochem. 2017;47:113–9. doi: 10.1016/j.jnutbio.2017.05.005.

Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health – A comprehensive review of human clinical trials. Mol Nutr Food Res. 2011;55(8):1129–41.

Patel KR, Scott E, Brown VA, Gescher AJ, Steward W, Brown K. Clin trials resveratrol. Ann N Y Acad Sci. 2011;1215:161–9. doi: 10.1111/j.1749-6632.2010.05853.x.

Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, et al. Health benefits of resveratrol: Evidence from clinical studies. Med Res Rev. 2019;39(5):1851–91. doi: 10.1002/med.21565.

Mirahmadi M, Azimi-Hashemi S, Saburi E, Kamali H, Pishbin M, Hadizadeh F. Potential inhibitory effect of lycopene on prostate cancer. Biomed Pharmacother. 2020;129:110459. doi: 10.1016/j.biopha.2020.110459.

Vahlensieck W, Theurer C, Pfitzer E, Patz B, Banik N, Engelmann U. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one year, randomized, placebo-controlled GRANU study. Urol Int. 2015;94(3):286–95. doi: 10.1159/000362903.

Damiano R, Cai T, Fornara P, Franzese CA, Leonardi R, Mirone V. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: A narrative review. Arch Ital Urol Androl. 2016;88(2):136–43. doi: 10.4081/aiua.2016.2.136.

Leibbrand M, Siefer S, Schon C, Perrinjaquet-Moccetti T, Kompek A, Csernich A, et al. Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia: A Pilot Study in Humans. J Med Food. 2019;22(6):551–9. doi: 10.1089/jmf.2018.0106.